These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 22184763)

  • 21. Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine.
    Scheithauer W; Blum J
    Oncology (Williston Park); 2004 Aug; 18(9):1161-8, 1173; discussion 1173-6, 1181-4. PubMed ID: 15471200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
    Caronia D; Martin M; Sastre J; de la Torre J; García-Sáenz JA; Alonso MR; Moreno LT; Pita G; Díaz-Rubio E; Benítez J; González-Neira A
    Clin Cancer Res; 2011 Apr; 17(7):2006-13. PubMed ID: 21325291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Capecitabine-induced hyperpigmentation].
    Vázquez-Bayo C; Rodríguez-Bujaldón AL; Jiménez-Puya R; Galán-Gutiérrez M; Moreno-Giménez JC
    Actas Dermosifiliogr; 2007 Sep; 98(7):491-3. PubMed ID: 17669305
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study of low-dose capecitabine monotherapy for metastatic breast cancer.
    Taguchi T; Nakayama T; Masuda N; Yoshidome K; Akagi K; Nishida Y; Yoshikawa Y; Ogino N; Abe C; Sakamoto J; Noguchi S;
    Chemotherapy; 2010; 56(2):166-70. PubMed ID: 20407245
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Capecitabine and hand-foot syndrome.
    Saif MW
    Expert Opin Drug Saf; 2011 Mar; 10(2):159-69. PubMed ID: 21174613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Hand-foot syndrome induced by chemotherapy: a case study].
    Simão DA; Lima ED; Souza RS; Faria TV; Azevedo GF
    Rev Bras Enferm; 2012; 65(2):374-8. PubMed ID: 22911424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer.
    El-Helw L; Coleman RE
    Breast; 2005 Oct; 14(5):368-74. PubMed ID: 16216738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Uncontrolled hypertriglyceridemia induced by capecitabine: case report and review of the literature.
    Bar-Sela G; Haim N
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):779-82. PubMed ID: 18641989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unilateral hand-foot syndrome: does it take sides? Case report and literature review.
    Almeida da Cruz L; Hoff PM; Ferrari CL; Riechelmann RS
    Clin Colorectal Cancer; 2012 Mar; 11(1):82-4. PubMed ID: 21764392
    [No Abstract]   [Full Text] [Related]  

  • 30. The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study.
    Ota M; Tatsumi K; Suwa H; Watanabe J; Watanabe K; Osada S; Tanaka K; Shoichi F; Ichikawa Y; Kunisaki C; Endo I
    Hepatogastroenterology; 2014 Jun; 61(132):1008-13. PubMed ID: 26158157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Actinic keratosis and capecitabine therapy.
    Higa GM; Kovach RF; Abraham J
    J Oncol Pharm Pract; 2005 Dec; 11(4):151-3. PubMed ID: 16595067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
    Aprile G; Mazzer M; Moroso S; Puglisi F
    Anticancer Drugs; 2009 Apr; 20(4):217-29. PubMed ID: 19247178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Moderate dose capecitabine in older patients with metastatic breast cancer: a standard option for first line treatment?
    Kotsori AA; Noble JL; Ashley S; Johnston S; Smith IE
    Breast; 2010 Oct; 19(5):377-81. PubMed ID: 20392643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy.
    Son HS; Lee WY; Lee WS; Yun SH; Chun HK
    Yonsei Med J; 2009 Dec; 50(6):796-802. PubMed ID: 20046420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of modified taohongsiwu decoction on patients with chemotherapy-induced hand-foot syndrome.
    Zhao C; Chen J; Yu B; Wu X; Dai C; Zhou C; Chen X
    J Tradit Chin Med; 2014 Feb; 34(1):10-4. PubMed ID: 25102684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Therapy traces on hands and feet in a patient with colon cancer].
    Stiefelhagen P
    MMW Fortschr Med; 2012 Jun; O 154 Suppl 2():9. PubMed ID: 22916416
    [No Abstract]   [Full Text] [Related]  

  • 37. [Adjuvant chemotherapy with capecitabine for colon cancer - a case series].
    Kuji M; Masuko H; Yamagami H; Matsumoto S; Tanioka T; Takahashi S; Ishizu H; Takahashi M
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):1752-4. PubMed ID: 25731318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Onycholysis with the appearance of a "sunset" secondary to capecitabine.
    Maino KL; Norwood C; Stashower ME
    Cutis; 2003 Sep; 72(3):234-6. PubMed ID: 14533836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A case of local-recurring breast cancer under long term-treatment by capecitabine].
    Yoneyama K; Takeshita T; Suzuki H; Morise M; Suzuki T; Kishi S; Tsutsui A; Matsumoto A
    Gan To Kagaku Ryoho; 2011 Dec; 38(13):2623-5. PubMed ID: 22189229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer.
    Venturini M; Paridaens R; Rossner D; Vaslamatzis MM; Nortier JW; Salzberg M; Rodrigues H; Bell R
    Oncology; 2007; 72(1-2):51-7. PubMed ID: 18004077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.